On Friday (July 26), the European Union’s drugs regulator, the Committee for Medicinal Products for Human Use (CHMP), advised that the drug lecanemab, a treatment for Alzheimer’s disease, should not be approved for use in the EU.
Jayne Sibley, the mastermind behind Sibstar, a debit card and mobile app aimed at those with dementia has secured a substantial £125K investment from BBC Dragons’ Den investors Sara Davies and Deborah Meaden.
Clinical-stage pharma company, PharmaKure which develops precision medicine for Alzheimer’s Disease and other neurological diseases has announced a collaboration agreement with one of the largest comprehensive universities in Malaysia.
Sygnature Discovery has launched an in vivo inflammation model, that the company says is ‘exciting but only the beginning’ of understanding life-limiting neuroinflammatory conditions.
A study looking at the feasibility of using repeated sampling of validated digital measures at home, in patients with early-stage Alzheimer’s Disease (AD), has completed enrollment for a multi-site study.
On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
Computer model predicts worsening cognitive scores, opening door to the use of machine learning in the selection of participants in Alzheimer’s disease trials.
Large clinical trials can be particularly useful in the early treatment and prevention of neurodegenerative diseases because of the amount of data collected, though patient recruitment and retention are challenging, says biostatistician.
Eli Lilly and Company and AC Immune have signed an agreement for the research and development of tau aggregation inhibitor small molecules, and AC Immune signed a strategic partnership with WuXi biologics.
Advanced Clinical is partnering with Cognitive Clinical Trials to overcome recruitment road blocks in Alzheimer’s clinical trials and expedite research through patient centric model.
Previous setbacks in Alzheimer’s disease research for disease-modifying treatments have set the stage for a pipeline of new medicines now moving into clinical trials, according to a recent PhRMA report.
At least 50,000 volunteers are needed to participate in clinical trials for Alzheimer’s disease – the global cost of which is expected to reach $2 trillion by 2030.
More flexible regulations on the path for approving potential Alzheimer's disease treatments represent a huge opportunity, according to the US FDA, CROs and research advocates.
Merz is hoping to further its Alzheimer’s research by licensing DiaGenic’s biomarkers for a transitional stage of disease, which is “very important” for stratification of clinical trials.
The UK's largest charity, the Wellcome Trust, has awarded £1.3m
(€1.9m) to fund the world's largest ever genome-wide association
study to identify the genetic origins of Alzheimer's disease.
US-based researchers have developed a transdermal vaccine for
Alzheimers disease which has been shown to clear brain-damaging
amyloid plaques in preclinical studies, offering hope to millions
of sufferers worldwide.
US drug developer Samaritan Pharmaceuticals has filed a patent for
a new drug that could treat a wide range of neurodegenerative
disorders, including Alzheimer's disease, by clearing out amyloid
plaques in the brain.
Scientists have uncovered a naturally occurring enzyme that can
break down a component of the brain plaques that play a central
role in Alzheimer's disease, which could provide researchers with a
basis for new therapies to treat...
Researchers believe that they have identified a drug target
molecule that could be used to treat mental impairment in people
with Down's syndrome paving the way for a treatment that could
improve the quality of life for sufferers.
A Phase I clinical trial, which is investigating the
pharmacological activities of a compound for the treatment of
Alzheimer's disease, has just been completed with results
indicating improved efficacy and pharmacokinetics over...
A handful of Alzheimer’s drug treatments and lifestyle-based
interventions shared the spotlight at the first ever Alzheimer’s
Association Prevention conference, in which scientists worldwide
took the opportunity to showcase the latest...
A new therapeutic technique based on a small molecule working in
tandem with a larger protein has been shown to block accumulation
of the brain-clogging amyloid protein seen in Alzheimer's disease,
raising the possibility of...
Researchers have identified a protein that protects the brain from
the destructive effects of Alzheimer's disease, protecting brain
cells by blocking another toxic protein that contributes to the
disease process
A study, which uses immunoglobulins to treat multiple sclerosis,
may also be able to help patients with Alzheimer's. The discovery
seems to point towards an approach, which treats Alzheimer's with
anti-bodies, which are...
Researchers in the US have taken an important step toward creating
a vaccine against Alzheimer's disease, overcoming the side effects
that held back a prior vaccine for the disease.
The first clinical trial of a peptide that mimics the cellular
adhesion molecule NCAM is due to take place in the UK in the third
quarter of this year, bringing a potential new treatment for
Alzheimer's disease a step closer,...
Scientists at Berlex Pharmaceuticals, the US subsidiary of
Germany's Schering, have identified a biologic marker for
Alzheimer's that could form the basis of a diagnostic test.
